Management Appointments and Updates at LRAD Corp., GenSpera, Inc., and InVivo Therapeutics
LRAD Corp. (LRAD-NASDAQ)
Earlier this week, long-range acoustic device provider LRAD Corp. appointed Bill VanDeWeghe to its Board of Directors as well as to its Compensation Committee. Mr. VanDeWeghe has a diverse background, with significant experience in both the business and legal arenas, as overviewed below.
Mr. VanDeWeghe is a managing director at RA Capital Advisors, where he heads the firm's defense industry team, developing strategies for clients and executing all facets of M&A transactions and financings. Mr. VanDeWeghe focuses on companies providing hardware, software, and services for defense, homeland security, and intelligence agency support. Mr. VanDeWeghe is also a senior strategic advisor and independent consultant for McKenna Long & Aldridge LLP's (MLA) San Diego office. Working with MLA's multidisciplinary team of attorneys across the country, Mr. VanDeWeghe advises and assists companies with corporate matters, business disputes, government contracting, and political issues. Prior to joining RA Capital Advisors in 2006, Mr. VanDeWeghe was a litigator for 15 years and a shareholder with a law firm where he worked with a broad variety of companies and professionals throughout Southern California assisting with numerous issues affecting their businesses. Mr. VanDeWeghe served as an artillery officer on active duty in the U.S. Army from 1983 to 1987, followed by a position commanding a firing battery in the Virginia National Guard. He was the Republican Party nominee for U.S. Congress, 53rd Congressional District, in 2002. Mr. VanDeWeghe earned a Bachelor's degree at Princeton University and a law degree at the Marshall-Wythe School of Law at the College of William and Mary. He is a FINRA-registered securities representative.
GenSpera, Inc. (GNSZ-OTC)
As well, GenSpera, Inc. appointed of Nancy Jean Barnabei, CPA as vice president finance and treasure. She is also serving as GenSpera’s principal accounting officer. As summarized below, Ms. Barnabei has experience developing and implementing operational and financial systems within growing biotech companies. GenSpera is currently preparing to commence a multi-center Phase II trial with its lead compound, G-202, in prostate cancer patients.
Ms. Barnabei has over 20 years of experience with both public and private companies in the pharmaceutical industry, in which she held a key role in the transition from fundraising to execution of growth strategies. Most recently, from 2010 to 2011, she was chief financial officer (CFO) of Corridor Pharmaceuticals, Inc., which acquired Immune Control, Inc., where she served as CFO from 2008 to 2010. Previously, she founded Talkeetna Advisors, LLC in 2005, where she provided services to emerging biotechnology companies, including budget development, long-range financial and operational planning, and accounting and reporting system implementation. Ms. Barnabei also served as vice president finance, treasurer and CFO of Locus Pharmaceuticals, Inc. from 2000 to 2004. She earlier served as Controller of Cephalon, Inc. (now part of Teva Pharmaceutical Industries Ltd. [TEVA-NASDAQ]), where she was responsible for Securities and Exchange Commission (SEC) reporting, tax strategies, and treasury, among other functions. She is a graduate of Northeastern University in Boston, Massachusetts.
InVivo Therapeutics Holdings Corp. (NVIV-OTC)
On Tuesday, August 21st, InVivo Therapeutics' chief executive officer (CEO) Frank Reynolds appeared on Boston’s ABC affiliate WCVB-TV during the 11:00 p.m. EDT newscast. The full segment is available via WCVB's website. InVivo is developing a novel treatment for traumatic spinal cord injuries (SCIs). The company is awaiting FDA approval to initiate human studies for its first SCI treatment.